Researcher.Life Logo

BMC Biotechnology : Impact Factor & More

eISSN: 1472-6750pISSN: 1472-6750
JournalOpen Access

Key Metrics

CiteScore
5
Impact Factor
< 5
SJR
Q2Biotechnology
SNIP
0.89
Recommended pre-submission checks
Powered by Paperpal by Editage

Topics Covered on BMC Biotechnology

BMC Biotechnology Journal Specifications

Indexed in the following public directories

  • Web of Science Web of Science
  • Scopus Scopus
  • DOAJ DOAJ
  • Inspec Inspec
  • SJR SJR
Overview
Publisher BMC
Language English
Frequency Continuous publication
Article Processing ChargesEUR 2290 | USD 2690 | GBP 1990
Publication Time20
Editorial Review ProcessAnonymous peer review
General Details
LanguageEnglish
FrequencyContinuous publication
Publication Start Year2000
Publisher URLVisit website
Website URLVisit website
Publication Details
PlagiarismVisit website
Publication Time 20
Waiver PolicyVisit website
Editorial Review Detail
Editorial TeamVisit website
Review ProcessAnonymous peer review
Review UrlVisit website
Information for authors
Author instructionsVisit website
Copyright DetailsVisit website
Deposit PolicySherpa/Romeo
License typeCC BY, CC0
OA statementVisit website
View less

Planning to publish in BMC Biotechnology ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in BMC Biotechnology

α-pinene and β-sitosterol co-loaded alginate/gelatin-functionalized niosomes for enhanced antibacterial and anti-biofilm activity against methicillin-resistant Staphylococcus aureus and carbapenem-resistant Klebsiella pneumoniae.
  • 16 May 2026
  • BMC biotechnology
B3GNT6 suppresses colorectal cancer progression by inhibiting the KRAS/ERK signaling pathway.
  • 14 May 2026
  • BMC biotechnology
Study on the mesoscopic characteristics of densified forming of shiitake mushroom residue biomass considering particle breakage.
  • 12 May 2026
  • BMC biotechnology
Affinity enhancement of an anti-VEGF humanized nanobody as a superior candidate to bevacizumab: integrative in silico and in vitro studies.
  • 12 May 2026
  • BMC biotechnology
PAM-flexible SpCas9 variants expand the targeting scope for porcine genome editing and cellular disease modeling.
  • 9 May 2026
  • BMC biotechnology
Gas vesicle-expressing human pluripotent stem cells enable multimodal ultrasound and optical coherence tomographic imaging.
  • 30 Apr 2026
  • BMC biotechnology
α-pinene and β-sitosterol co-loaded alginate/gelatin-functionalized niosomes for enhanced antibacterial and anti-biofilm activity against methicillin-resistant Staphylococcus aureus and carbapenem-resistant Klebsiella pneumoniae.
  • 16 May 2026
  • BMC biotechnology
B3GNT6 suppresses colorectal cancer progression by inhibiting the KRAS/ERK signaling pathway.
  • 14 May 2026
  • BMC biotechnology
Study on the mesoscopic characteristics of densified forming of shiitake mushroom residue biomass considering particle breakage.
  • 12 May 2026
  • BMC biotechnology
Affinity enhancement of an anti-VEGF humanized nanobody as a superior candidate to bevacizumab: integrative in silico and in vitro studies.
  • 12 May 2026
  • BMC biotechnology
PAM-flexible SpCas9 variants expand the targeting scope for porcine genome editing and cellular disease modeling.
  • 9 May 2026
  • BMC biotechnology
Gas vesicle-expressing human pluripotent stem cells enable multimodal ultrasound and optical coherence tomographic imaging.
  • 30 Apr 2026
  • BMC biotechnology

FAQs on BMC Biotechnology